- Internship - Massachusetts General Hospital (1989-1990), Medicine
- Residency - Massachusetts General Hospital (1990-1993), Neurology
- Fellowship - Instituto Scientifico San Raffaela Hospital (1993-1995), Neurophysiology
- Medical School - Harvard Medical School (1985-1989)
- Fellowship - UCLA (1995-1997), Epilepsy/eeg
Mark Agostini, M.D.
Director, Epilepsy Monitoring Unit, Parkland Health & Hospital System
- Distinguished Teaching Professor
- Epilepsy & Seizures
Dr. Agostini received his medical degree at Harvard Medical School and completed his neurology residency at Massachusetts General Hospital, a teaching affiliate of Harvard Medical School. He completed a fellowship in neurology at the UCLA School of Medicine, as well as a fellowship in clinical neurophysiology at the Instituto Scientifico San Raffaela Hospital in Milan, Italy.
Dr. Agostini is active in clinical research as well as patient care. Among other projects, he was the principal investigator for the drug lacosamide (sold under the brand name Vimpat), which works in combination with other medications to help control seizures.
He has been named a Super Doctor by Texas Monthly and a Best Doctor by D Magazine. He is board certified by the American Board of Psychiatry and Neurology. He has received several teaching awards from UT Southwestern medical students and neurology residents.
Meet Dr. Agostini
When Mark Agostini, M.D., treats epilepsy patients at UT Southwestern Medical Center, he lives by the words of Winston Churchill: Never, never, never give up.
"We cure seizures.”
He relentlessly tracks down the cause of patients’ seizures and finds the treatment that works for them, with one goal in mind: stopping the seizures.
Each epilepsy patient is unique. What works for some won’t work for others, he says. As a result, each patient presents a challenge that requires the skills of a neurology specialist.
“We are relentless. We just don’t give up,” says Dr. Agostini, a graduate of Harvard Medical School.
Finding the right treatment means balancing quality of life, but the first step is always aimed at stopping the seizures. Dr. Agostini and the epilepsy team at UT Southwestern have access to the latest technologies and treatments to help find the answer. This includes UT Southwestern’s Epilepsy Monitoring Unit, which allows Dr. Agostini to see a patient’s seizure firsthand.
A researcher as well as a clinician, Dr. Agostini also is involved in experimental therapies such as intracranial stimulators and experimental anti-seizure medications that are in clinical trials. In several cases, his patients have benefited directly from this research. He was the principal investigator for the drug lacosamide (sold under the brand name Vimpat), which works in combination with other medications to help control seizures. Each anti-seizure medication brought to FDA approval offers a patient a chance to become seizure-free, Dr. Agostini says.
Dr. Agostini’s epilepsy patients have complex medical problems. When other doctors are needed, Dr. Agostini can rely on a multidisciplinary team that includes neuroradiologists, neuropsychologists, and neurosurgeons. Not many medical centers can offer that.
Working together, Dr. Agostini and the UTSW team achieve his ultimate goal as a physician treating epilepsy patients: “We give people their life back.”
- American Board of Clinical Neurophysiology
- American Board of Registration of Electroencephalographic and evoked potential Technologists
- Professional Advisory Board Epilepsy Foundation, Greater North Texas
- Outstanding Faculty Teaching Award 2000, UT Southwestern
- Outstanding Resident Teaching Award 1997, UCLA
- Glaxo Young Investigator Award 1996
- Merritt-Putnam Award 1995
- Topscholar Award 1996
Treatment of drug-resistant epilepsy in patients with periventricular nodular heterotopia using RNS® System: Efficacy and description of chronic electrophysiological recordings.
Nune G, Arcot Desai S, Razavi B, Agostini MA, Bergey GK, Herekar AA, Hirsch LJ, Lee RW, Rutecki PA, Srinivasan S, Van Ness PC, Tcheng TK, Morrell MJ, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2019 May 130 8 1196-1207
Diagnostic Yield of 2-Hour EEG Is Similar With 30-Minute EEG in Patients With a Normal 30-Minute EEG.
Mahuwala Z, Ahmadi S, Bozoky Z, Hays R, Agostini M, Ding K, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society 2019 Feb
Neurological Autoantibody Prevalence in Epilepsy of Unknown Etiology.
Dubey D, Alqallaf A, Hays R, Freeman M, Chen K, Ding K, Agostini M, Vernino S JAMA neurology 2017 Feb
Temporal lobe volume predicts Wada memory test performance in patients with mesial temporal sclerosis.
Ding K, Gong Y, Modur PN, Diaz-Arrastia R, Agostini M, Gupta P, McColl R, Hays R, Van Ness P Epilepsy research 2015 Nov 120 25-30
Retrospective case series of the clinical features, management and outcomes of patients with autoimmune epilepsy.
Dubey D, Samudra N, Gupta P, Agostini M, Ding K, Van Ness PC, Vernino S, Hays R Seizure 2015 Jul 29 143-7
Bilateral memory dysfunction in epilepsy surgery candidates detected by the intracarotid amobarbital procedure (Wada) test.
Diaz-Arrastia, RR; Frol, AB; Agostini, MA; Lacritz, LH; Van Ness, PC Epilepsia 2000 41(Suppl. 7) 127
Estimated and current intellectual function in patients with intractable epilepsy.
Frol, AB; Garcia, MC; Agostini, MA; Van Ness PC; Cullum, CM; Diaz-Arrastia, RR Epilepsia 2001 42 (Suppl. 7) 239
Temporal intermittent rhythmic delta activity: Prevalence, lateralization and MRI correlation in an adult outpatient population.
Garcia, MC; Agostini, MA; Diaz-Arrastia, RR; Van Ness, PC Epilepsia 2001 42(Suppl. 7)/ 25
- Treatment of drug-resistant epilepsy in patients with periventricular nodular heterotopia using RNS® System: Efficacy and description of chronic electrophysiological recordings.
- Epilepsy & Seizures